Pathway_id | Description | Adj p value | Genes involved |
---|---|---|---|
bioplanet_1345 | FOXM1 transcription factor network | 1.87E-05 | AURKB, BIRC5, CCNA2, CENPF, FOXM1, CENPA, CCNB2, CCNB1, PLK1, NEK2 |
bioplanet_592 | Aurora B signaling | 1.03E-04 | STMN1, AURKB, CDCA8, BIRC5, CENPA, NCAPG, INCENP, KIF23, KIF20A |
bioplanet_1622 | Phosphorylation of Emi1 | 3.82E-04 | FBXO5, CDC20, CCNB1, PLK1 |
bioplanet_67 | Stathmin and breast cancer resistance to antimicrotubule agents | 1.40E-03 | HIST1H4C, STMN1, CREB1, OAS1, USP18, HLA-B, STAT1, GBP1, CXCL10, PRKACB, IRF1, IFIT2, KAT2B, IFI6, TAP1, ISG15, EIF2AK2, RNF14, CCNB1, STAT2, PSMB9, IRF9 |
bioplanet_1327 | Polo-like kinase 1 (PLK1) pathway | 1.79E-03 | FBXO5, CDC20, PRC1, INCENP, CCNB1, SPC24, PLK1, KIF20A |
bioplanet_1757 | Hypertrophy pathway | 5.99E-03 | IFRD1, ATF3, VEGFA, CYR61, IL1A |
bioplanet_1391 | APC/C activator regulation between G1/S and early anaphase | 7.36E-03 | FBXO5, CDC20, UBE2C, CCNB1, PLK1 |
bioplanet_1363 | Delta Np63 pathway | 1.09E-02 | NRG1, FASN, RRAD, TOP2A, CCNB2, IL1A, RAB38 |
bioplanet_235 | Cytokine-cytokine receptor interaction | 1.31E-02 | TNFSF13B, CSF3, IL11RA, INHBE, CXCL5, TNFSF10, CSF1R, CXCL10, CCL2, IL20RB, CCL20, CXCL2, LEP, VEGFA, IL1A, IL6, IL24, TNFRSF10D, CCL8 |
bioplanet_884 | APC/C- and Cdc20-mediated degradation of Nek2A | 1.47E-02 | MAD2L1, CDC20, UBE2C, CCNB1, NEK2 |
bioplanet_1511 | Cyclin A/B1-associated events during G2/M transition | 1.49E-02 | CCNA2, CCNB2, CCNB1, PLK1 |
bioplanet_195 | p53 activity regulation | 1.92E-02 | GADD45A, KAT2B, SESN2, CCNA2, CCNE2, SHISA5, CCNB2, PMAIP1, GTSE1, CCNB1, CCND2 |
bioplanet_1575 | Kinesins | 1.95E-02 | KIF22, KIFC1, KIF11, KIF23, KIF20A |
bioplanet_1139 | MicroRNA regulation of DNA damage response | 2.19E-02 | CREB1, MCM7, GADD45A, CCNE2, CCNB2, PMAIP1, CCNB1, CCND2 |
bioplanet_1409 | Mitotic prometaphase | 2.82E-02 | ZWINT, CDC20, CENPF, CENPA, INCENP, PLK1 |